PPD first to migrate data to the Oracle Health Sciences Cloud
Thursday, March 26, 2015
PPD is the first company to migrate trials from an on-site installation of Oracle Health Sciences’ Siebel Clinical Trial Management System to Siebel Clinical Trial Management System Cloud Service—creating a highly available, centralized trial database that lowers costs, simplifies management, improves the accuracy of multi-CRO clinical trial data and accelerates studies.
Oracle’s cloud service “dramatically simplifies how we manage study data and communicate with clients, especially in studies involving multiple CROs,” said Andrew Masters, vice president of enterprise information management for PPD. “Clients now can access study data through Oracle’s Siebel Cloud Service, so we no longer need to send data back and forth to them, saving us time, reducing the cost of studies and creating better results for our clients.”
Using Siebel Clinical Trial Management System Cloud Service with a standardized clinical trial management system (CTMS) configuration, PPD migrated data from 124 studies to the Oracle Health Sciences Cloud in just six weeks. In addition, PPD is reducing the in-house resources needed to support these trials by using the cloud to simplify the exchange of data for multi-CRO studies.
The service “delivers comprehensive clinical trial management with all the performance, scalability and cost benefits of Oracle Health Sciences Cloud,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. “The success of PPD in rapidly migrating data from an on-premises environment to Siebel Clinical Trial Management System Cloud Service demonstrates the flexibility of the solution and its ability to simplify data exchange, ultimately leading to more efficient clinical trial management.”
The system combines standardized, comprehensive clinical trial capabilities, integrated analytics tools and unsurpassed data security with a cloud service that lets organizations effectively and economically manage trial activities and improve CRO and sponsor relationships from early- to late-stage clinical trials.